Lawmakers Eye Biosimilar-Delay Deals, But None Are Here Yet | White & Case LLP International Law Firm, Global Law Practice
Lawmakers Eye Biosimilar-Delay Deals, But None Are Here Yet

Lawmakers Eye Biosimilar-Delay Deals, But None Are Here Yet

Pay-for-delay deals help drug makers fend off competition of their pharmaceutical products from generic alternatives. Biological therapies, a new form of treatment options, have also become the focus of pay-for-delay deals. Lawmakers have taken notice, and are now including biologics in pay-for-delay legislation.

White & Case Antitrust/Competition Partners Eric Grannon and Jack Pace spoke to Law360 about the pay-for-delay cases affecting biologics. Go to Law360 to read their thoughts on pay-for-delay legislation and litigation, patent settlements and more.